People with chronic obstructive pulmonary disease, or COPD, often face sudden breathing flare-ups called exacerbations. These events make life harder and can lead to hospital visits. A new study looked at a drug called astegolimab to see if it could stop these attacks. The trials involved over 2,600 current or former smokers who had frequent flare-ups in the past. They received the drug under the skin every two weeks or every four weeks, or a fake treatment. The goal was to lower the yearly rate of moderate or severe breathing attacks.
The results showed mixed but promising signs. In one trial group, taking the drug every two weeks clearly lowered the number of flare-ups. Another group taking it every four weeks also saw fewer attacks. However, in other trial groups, the difference between the drug and the fake treatment was not statistically significant. This means the benefit depended on the specific trial design and how often patients took the medicine.
Safety checks found that most participants experienced side effects, but these were mostly common colds or chest infections. Serious problems were not reported, and the side effects were balanced between those taking the drug and those taking the placebo. The findings suggest this new approach might help people who have few other treatment choices for their breathing issues.
